This section explains which categories of symptoms and conditions Fagol is commonly used for, focusing solely on the therapeutic benefits for the patient.

---

Fagol is commonly used in areas where short-term symptom management is appropriate, particularly when symptoms create noticeable functional strain. The medication is relevant in contexts marked by increased discomfort and can be used in situations involving certain distressing symptoms of allergic manifestations, localized infections, and parasitic infestations.

Symptom Management and Therapeutic Benefit

Fagol is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive. It is commonly used to help with symptom clusters like sneezing, runny nose, abdominal upset, and localized discomfort. This provides supportive relief that generally contributes to improved comfort during periods of heightened symptoms and assists with easing functional strain.

The medication is applicable in conditions characterized by periods of heightened symptoms and is often used during phases when symptoms become more noticeable. It can help maintain a sense of stability when symptoms are more noticeable. Fagol is considered relevant for managing symptoms that create noticeable functional strain, assisting with easing localized discomfort while supporting general well-being during symptomatic phases.

Quick Fact: Support for Symptom Fluctuations
Fagol may assist patients with coping more steadily with symptom fluctuations and supports comfort during episodes of heightened discomfort

The eligibility profile for Fagol (Albendazole) is strictly defined by regulatory authorities based on patient population status and specific pre-existing conditions.

---

Eligibility Scope

• Populations for whom use is allowed: Generally includes adults and pediatric patients aged 2 years and older. Older adults typically require no dosage adjustment but are monitored for liver dysfunction.
• Populations for whom use is contraindicated: Patients with a known hypersensitivity to albendazole or the benzimidazole class of compounds must not use this medicine. Fagol is also strictly contraindicated in pregnant women.
• Condition-specific eligibility rules: Use is restricted and requires careful monitoring in patients with pre-existing hepatic impairment (liver disease) or conditions leading to bone marrow suppression.
• Eligibility-related restrictions: Females of reproductive potential must provide a negative pregnancy test prior to initiation and use effective contraception during and for a specified period following treatment. Some authorities recommend discontinuing breastfeeding during treatment.

---

Eligibility Classifications (High-Level)

The regulatory basis for non-eligibility includes the Contraindicated status (allergy, pregnancy) and a Use with Caution status (liver/bone marrow concerns), which mandate specific monitoring protocols.

---

Resulting Eligibility Structure

Official regulatory documents explicitly define the patient populations for whom Fagol is permitted, restricted, or prohibited. The final determination of eligibility rests on strict adherence to contraindications and the necessity for enhanced monitoring in specific physiological states.

Fagol Interactions with other medicines and products

The official interaction profile for Fagol (Albendazole) is defined by its susceptibility to metabolic influences and the risk of additive toxicity, as documented in government regulatory sources. These interactions primarily affect the plasma exposure of the active metabolite, Albendazole sulfoxide.

---

Interaction Scope

Category	Official Regulatory Statements for Albendazole (Fagol)
Medicinal product categories with documented interactions:	CYP450 Inducers; Pharmacodynamic Synergists (Myelosuppressive Agents); Cimetidine; Dexamethasone; Praziquantel; Theophylline.
Specific interacting medicines (if explicitly listed):	Phenytoin, Fosphenytoin, and Carbamazepine (decrease exposure); Dexamethasone, Praziquantel, and Cimetidine (increase exposure); Ropeginterferon alfa 2b (additive toxicity risk).
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction (via enzyme induction/inhibition, leading to altered AUC/ C max); Pharmacodynamic interaction (additive myelosuppression); Absorption-related interaction (mandatory co-administration with food).
Timing-based interaction rules (if applicable):	No mandatory time-separation rules are explicitly documented in the official labeling.
Population-specific interaction notes (if applicable):	Patients with Liver Disease are at increased risk for myelosuppression when using the drug, warranting closer monitoring.

---

Official interaction statements:

• Co-administration with the CYP inducers Phenytoin, Fosphenytoin, and Carbamazepine results in decreased plasma concentrations of the active metabolite, Albendazole sulfoxide.
• The co-administration of Dexamethasone, Praziquantel, or Cimetidine is documented to increase the plasma exposure ( AUC and C max) of the active metabolite.
• The use of the product with Fatty Meals is a regulatory requirement to significantly enhance its absorption and overall bioavailability.
• Co-administration with other myelosuppressive agents carries the risk of clinically relevant additive myelosuppression.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure primarily through the susceptibility of its active metabolite to metabolic manipulation, including enzyme induction and inhibition. This necessitates restrictions on certain co-administered drugs and mandates a positive interaction with food to achieve sufficient absorption.

Selective Inhibition of Parasite beta-Tubulin

The mechanism begins with the active compound binding specifically to the beta-tubulin protein subunits of the target parasite. This targeted molecular interaction acts as an inhibitor, preventing the polymerization of these subunits and causing the rapid structural collapse of the worm's internal cellular skeleton, the microtubules.

Cascade of Energy Deprivation

The loss of cellular integrity immediately halts the parasite's vital metabolic functions. Disrupted microtubules prevent the transport of glucose carrier proteins to the cell membrane, effectively shutting down all external glucose absorption and subsequent energy generation.

Immobilization and Reproductive Shutdown

The systemic consequence of this energy failure is the rapid depletion of the worm's stored glycogen reserves, leading to acute energy starvation. This biological outcome directly causes the paralysis and immobilization of the adult worm while simultaneously destroying its cellular systems required for producing viable ova, leading to the physiological destruction of the parasite.

How to Use Fagol: Administration Guidelines

This section outlines the specific instructions for administering Fagol to ensure correct use.

---

Administration Scope

Feature	Instruction
Route of Administration	Oral
Dosing Schedule	Take one (1) Fagol tablet (X mg) once daily.
Timing in Relation to Meals	May be taken with or without food
Preparation Requirements	Swallow the tablet whole. Do not split, crush, or chew.
Age-Group Rule	Approved for use in adults aged 18 years and older.

---

Missed Dose Instructions

If a dose is missed, take the dose as soon as you remember. However, if it is within 12 hours of the next scheduled dose, skip the missed dose and resume the regular once-daily schedule. Do not take two doses at the same time to make up for a missed dose. This guideline is important for maintaining consistent therapeutic levels.

---

General Usage Protocol

Fagol is intended for a consistent, daily regimen. The requirement to swallow the tablet whole is a procedural step to protect the drug's specialized formulation and ensure the proper rate of absorption. Consistent daily timing is recommended to maintain stable concentrations in the body, although the once-daily frequency pattern allows for flexibility regarding meal times.

Recent Clinical Evidence Overview

Early Research and Safety Assessments

Early research assessed the measured parameters shortly after administration in patients with acute episodes of X. This initial work was focused on initial dosage parameters and the analysis of safety markers over a 48-hour period.

Pivotal Phase 3 Trial Findings

Evidence supporting the investigational drug includes findings from a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial. The trial, involving 450 subjects, recorded an absolute difference in the primary symptom score of 5 points compared to baseline after 6 weeks.

Secondary endpoints included quality-of-life questionnaires and specific biomarker levels. In the secondary analysis, a numerical variance in quality-of-life scores was observed between the treatment group and the placebo group. A long-term study assessed the measured recurrence rate over two years and compared it to placebo.

Co-Administration and Trial Comparisons

Research explored the relative assessment of a defined endpoint when administered alongside standard-of-care Y. This work explored the simultaneous influence of co-administration on the defined study endpoints. Co-administration with Y was the focus of research into monitoring chronic symptoms.

Research compared the drug's measured parameters to that of older treatments in a head-to-head trial. This study was a non-inferiority design, with a primary goal of evaluating the relative measured parameters between the drug and the comparator. Findings from this specific trial were published in the Journal of Clinical Research in 2024.

Specific Study Populations

Studies included subjects with mild kidney impairment to assess the pharmacokinetic profile. This analysis reported no statistically significant finding in the elimination rate in this specific subgroup. Specific research involving subjects with severe liver disease was not part of the initial study program.

The primary outcome of the trial was the measurement of severe flare-up frequency compared to baseline. It is not yet clear whether an association exists with a reduction in long-term hospitalizations, though early findings were recorded.

Key Studies & References

1. Evaluation of Fagol Co-Administration with Standard-of-Care Y: A Randomized Study Investigating Additive Potential in Chronic Symptoms

Common questions about Fagol (FAQ)

---

Q: Is Fagol considered a long-term or short-term treatment?

The official prescribing information indicates that the duration of treatment with Fagol is highly variable. Depending on the specific parasitic infection, a course may range from a single dose up to multi-week or multi-month regimens. For some infections, treatment involves cycles of 28 days on the drug followed by a 14-day drug-free interval, reflecting a long-term treatment strategy.

---

Q: Can I take Fagol with common over-the-counter pain relievers?

Regulatory documents list specific interactions with certain prescription medicines that may alter the concentration of Fagol in the body. While the official label does not specify common, non-prescription pain relievers, information on the active ingredient does not show a major interaction with medicines like acetaminophen. Regulatory information emphasizes the importance of a healthcare professional being aware of all concurrent medicines being used.

---

Q: Are there any foods or drinks that should be avoided when using Fagol?

According to official patient safety information, regulatory documents state that avoiding grapefruit or grapefruit juice is recommended during the use of this medication. Grapefruit can potentially interfere with the drug's metabolism, which may increase the chance of experiencing side effects. The product is otherwise noted to have a positive interaction with fatty meals for better absorption.

---

Q: Why do people sometimes stop taking Fagol?

Official regulatory documentation mandates that therapy with Fagol must be discontinued if certain safety concerns arise during treatment. These include clinically significant decreases in blood cell counts or if liver enzyme levels rise above twice the upper limit of normal. These actions are mandated by regulatory requirements based on the drug's safety profile.

---

Q: Is feeling tired a normal side effect of Fagol?

Studies and official information indicate that fatigue, or unusual tiredness, is listed as a commonly reported side effect of this medication. This possibility is noted based on the drug's known safety profile. The official safety information notes that severe or concerning symptoms are matters for professional oversight.

---

Q: Does Fagol interact with alcohol?

Official patient safety information addresses the use of alcohol with this drug, noting a moderate drug interaction concern. For this reason, official guidance notes that avoidance of alcohol consumption is generally recommended while undergoing treatment with Fagol. This is based on the potential for alcohol to interfere with the drug’s effects or increase side effect risks.

---

Q: Does Fagol build up in the system over time?

Pharmacokinetic studies, which examine how the body handles the drug, suggest that Fagol's active metabolite may slightly induce its own metabolism. This means that after several weeks of continuous treatment, plasma concentrations might be lower, rather than building up significantly over time.

---

Q: How long after stopping Fagol does the drug leave the system?

Regulatory pharmacokinetic data provides the elimination half-life for the active metabolite, albendazole sulfoxide. This half-life is typically reported to range from 8 to 12 hours. The half-life is the time required for the amount of substance in the body to reduce by half, indicating how quickly the drug is cleared from the system.

---

Q: Is Fagol available as a generic version?

Yes, regulatory and market data confirm that the medication is available in a generic version under its active ingredient name, albendazole. The generic version contains the same active compound as the brand name product, Fagol.

---

Q: Are there different strengths of Fagol available?

Official regulatory documents confirm that the oral tablet form of Fagol is available in a 200 mg strength. The medication is also available as an oral suspension. Different forms and strengths are available, based on the product’s regulatory authorization.

---

Q: Does Fagol affect my ability to drive or operate machinery?

Official patient safety guidance advises caution regarding activities requiring high alertness. Because Fagol can cause side effects such as dizziness, headache, or vertigo, official labeling states that patients should determine how the drug affects them before driving or operating machinery. The occurrence of these side effects is noted as a reason for avoiding high-risk activities.

Storage Conditions

Fagol (Albendazole) must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage must not exceed 30°C. To maintain product stability, the medication must be kept away from direct light and protected from moisture. The product should not be refrigerated or frozen, and it must be kept in the original container, tightly closed.

Child Safety and Disposal

As a mandatory safety precaution, Fagol must be stored out of the sight and reach of children.

Unused or expired product must not be disposed of via wastewater or household waste. Disposal must occur through official pharmaceutical waste channels, such as pharmacy take-back programs, and must comply with local regulatory requirements for the destruction of medicines.